bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19
Authors: Duivenvoorden Raphaël , Vart Priya , Noordzij Marlies , Soares dos Santos Augusto C. , Zulkarnaev Alex B. , Franssen Casper F. M. , Kuypers Dirk , Demir Erol , Rahimzadeh Hormat , Kerschbaum Julia , Jager Kitty J. , Turkmen Kultigin , Hemmelder Marc H. , Schouten Marcel , Rodríguez-Ferrero María Luisa , Crespo Marta , Gansevoort Ron T. , Hilbrands Luuk B. ,   ERACODA Collaborators
Published: March 2022

Background.
Kidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)–related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19.

Methods.
We analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021.

Results.
We included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre–COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status.

Conclusions.
In kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.
A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada
Authors: Qureshy Kamran , Ross Kirk Andreas , Lyng Wolden Michael , Abbas Mohseni Zonoozi Amir , Liu Aiden 
Published: March 2022

We assessed physicians’ experiences of prescribing once-weekly (OW) semaglutide to patients with type 2 diabetes (T2D) in Canada. Physicians who had prescribed OW semaglutide to ≥2 patients with T2D in the past 12 months and had been doing so for ≥3 months were surveyed during 1–17 October 2018. Prescribing reasons, treatment satisfaction and reasons for discontinuation were assessed. Of the 50 participants, 72% and 54% were prescribed OW semaglutide due to its superior glycemic control and effect on weight, respectively. Most physicians were more satisfied with injection frequency (62%), effect on weight (60%), achieving HbA1c target (54%) and therapy simplicity (50%) with OW semaglutide versus other glucagon-like peptide-1 receptor agonists. Treatment discontinuations in 13% of OW semaglutide-treated patients were reported by physicians, primarily due to gastrointestinal symptoms (70%). The survey suggests that physicians are satisfied with the OW semaglutide clinical effects.
Video Abstract: http://links.lww.com/CAEN/A34
Administration approaches of nursing assistants in hospitals: a scoping review
Authors: Zeng Ben-tuo , Jin Ying-hui , Cheng Shu-dong , Ding Yan-ming , Du Ji-wei 
Published: March 2022

AbstractObjectivesThe administration of nursing assistants is closely associated with patient outcomes, but the current situation needs improvement. Studies evaluating intrahospital administration of nursing assistants are limited, and there is a lack of available evidence-based reviews in this field. This study aimed to identify existing literature on intrahospital nursing assistants’ administration approaches.DesignScoping review.Search strategyWe searched fifteen electronic databases for English and Chinese articles published between January 2011 and March 2022. Publications on administration approaches, models and appraisal tools of intrahospital nursing assistants were included.ResultsThirty-six studies were eligible for the review with acceptable quality. We identified one administration model, nine administration methods, fifteen educational programs, and seven appraisal tools from the included studies. The frequency effect size analysis yielded 15 topics of the main focus at four levels, suggesting that included articles were mainly (33%) focused on the competency of nursing assistants, and the lectures were the most (80%) used strategy in quality improvement projects. Evidence from the studies was of low-to-moderate quality, indicating huge gaps between evidence-based research and management practice.ConclusionsA series of practical intrahospital administration approaches was revealed, and fifteen primarily focused topics were identified. We should explore this area more thoroughly using structured frameworks and standardized methodology. This scoping review will help managers find more effective ways to improve the quality of care. Researchers may focus more on evidence-based practice in nursing assistant administration using the 15 topics as a breakthrough.Strengths and limitationsFirst scoping review of practical administration approaches for nursing assistants in hospitals.Presenting the main topics and focus of related articles.Development of the nursing assistant administration was widely varied among countries.Most of the included studies were of moderate-to-low methodological quality, and a huge gap exists between evidence-based research and management practice.
Protocol for an automated, pragmatic, embedded, adaptive randomised controlled trial: behavioural economics-informed mobile phone-based reminder messages to improve clinic attendance in a Botswanan schools-based vision screening programme
Authors: Allen Luke , Ratshaa Bakgaki , Macleod David , Bolster Nigel , Burton Matthew , Kim Min , Bastawrous Andrew , Ho-Foster Ari , Chroston Hannah , Nkomazana Oathokwa 
Published: March 2022

AbstractBackgroundClinic non-attendance rates are high across the African continent. Emerging evidence suggests that phone-based reminder messages could make a small but important contributing to reducing non-attendance. We used behavioral economics principles to develop an SMS and voice reminder message to improve attendance rates in a school-based eye screening programme in Botswana.MethodsWe will test a new theory-informed SMS and voice reminder message in a national school-based eye screening programme in Botswana. The control will be the standard SMS message used to remind parents/guardians to bring their child for ophthalmic assessment. All messages will be sent three times. The primary outcome is attendance for ophthalmic assessment. We will use an automated adaptive approach, starting with a 1:1:1:1 allocation ratio. Patients will not be blinded,DiscussionAs far as we are aware, only one other study has used behavioral economics to inform the development of reminder messages to be deployed in an African healthcare setting. Our study will will use an adaptive trial design, embedded in a national screening programme. Our approach can be used to trial other forms of reminder message in the future.Trial registrationISRCTN:96528723. Registered 5th January 2022, https://doi.org/10.1186/ISRCTN96528723Administrative informationNote: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).
Palliative care in the treatment of women with breast cancer: a scoping review protocol
Authors: Velasco-Yanez Romel Jonathan , Fernandes Ana Fátima Carvalho , Mattos Samuel Miranda , Moreira Thereza Maria Magalhães , Castro Régia Christina Moura Barbosa , Lopes-Junior Luís Carlos 
Published: March 2022

Introduction: Palliative care is an approach that improves patients' quality of life and their families when they face problems inherent to a life-threatening illness. In the current scenario where breast cancer ranks first among the most common types of cancer in women, research has revealed little control by these patients over the symptoms of the disease and its treatment, resulting in poor quality of life, which should be the focus of attention of palliative care. Thus, the purpose of this study is to map and synthesize the available evidence on palliative care in treating breast cancer women.
Methods: This scoping review protocol was elaborated following the methodological recommendations proposed by the Joanna Briggs Institute (JBI) and the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist. All study designs, experimental studies, observational studies, qualitative studies, mixed studies, and reviews reporting the palliative care for breast cancer women, will be considered. The following electronic databases will be searched: MEDLINE (via PubMed), Embase, Cochrane Library, Web of Science, Scopus, JBI Evidence Synthesis, Epistemonikos, CINAHL (via EBSCO), LILACS, and the electronic repository SciELO. In addition, The British Library, Google Scholar, Preprints for Health Sciences [medRXiv], Open Grey, Who Library Database, ProQuest Global Dissertations and Theses, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform will be searched. No language or date restriction will be applied in the search strategy. Two investigators will independently select studies and perform data extraction and critical appraisal using the using JBI design-specific tolos. A narrative synthesis of the evidence will be carried out and will be grouped and presented in tables and graphic models. Also, a similarity analysis will be performed using IRaMuTeQ software version 0.7 alpha 2, leading to textual categories and themes.
Expected Results: The findings of this review will help to identify the gaps for the design of future primary research on women with breast cancer in palliative care. Ultimately, will position care services, managers, and health professionals in the knowledge of the phenomenon, so that they can implement the best evidence-based palliative care practices and improve the quality of care provided to breast cancer patients.
Open Science Framework Registration: osf.io/5bwq7
Quantifying formations of Neutravidin clusters on biotinylated mixed silane Self-Assembled Monolayers
Authors: Ghosh Ushnik 
Published: March 2022

AbstractTowards the goal of developing bio-chip / lab-on-a-chip substrates capable of performing highly specific bio-chemical reactions, Neutravidin binding to mixed Biotinylated Silane Self-Assembled Monolayers were studied using Confocal Fluorescence Light Microscopy. Non-specific bindings, specifically the formations of Neutravidin clusters, were quantified. Several experiments were conducted to determine the concentrations of Neutravidin necessary to not saturate surface binding to Biotinylated Self-Assembled Monolayers, determine the effectiveness of using FBS blocking buffers to reduce non-specific binding, optimize the repeatability of Neutravidin binding to Biotinlyated mixed Self-Assembled Monolayers with Silane-PEG-Biotin compositions ranging from 0 to 15%, and quantify background Neutravidin bindings and the corresponding formations of Neutravidin clusters to Self-Assembled Monolayers as Silane-PEG-Biotin percent compositions increase from 0 to 15%. The Neutravidin, Silane-PEG-Biotin, and Silane mPEG concentrations and ratios needed to develop homogeneous Neutravidin films, without the formations of clusters, on the Self-Assembled Monolayers have been determined.
The Arabidopsis transcription factor NLP2 regulates early nitrate responses and integrates nitrate assimilation with energy and carbon skeleton supply
Authors: Durand Mickaël , Brehaut Virginie , Clément Gilles , Kelemen Zsolt , Macé Julien , Feil Regina , Duville Garry , Launay-Avon Alexandra , Roux Christine Paysant-Le , Lunn John E. , Roudier François , Krapp Anne 
Published: March 2022

AbstractNitrate signaling improves plant growth under limited nitrate availability and, hence, optimal resource use for crop production. Ongoing work has identified several transcriptional regulators of nitrate signaling, including the Arabidopsis thaliana transcription factor NIN-LIKE PROTEIN 7 (NLP7), but additional regulators likely remain to be identified. Here, we characterized Arabidopsis NLP2 as a master upstream transcriptional regulator of early nitrate responses that interacts with NLP7 in vivo and shares key molecular features such as nitrate-dependent nuclear localization, a DNA binding motif, and some target genes with NLP7. Additional genetic, genomic and metabolic approaches revealed a specific role for NLP2 in the nitrate-dependent regulation of carbon and energy-related processes that likely influence plant growth under distinct nitrogen environments. Our findings highlight the complementarity and specificity of NLP2 and NLP7 in orchestrating a multi-tiered nitrate regulatory network that links nitrate assimilation with carbon and energy metabolism for efficient nitrogen use and biomass production.One-sentence summaryNLP2 and NLP7 orchestrate plant responses to nitrate supply and control nitrate- dependent regulation of carbon and energy metabolism.
Longitudinal changes of white matter hyperintensities in sporadic small vessel disease: a systematic review and meta-analysis
Authors: Jochems Angela CC , Arteaga Carmen , Chappell Francesca M , Ritakari Tuula , Hooley Monique , Doubal Fergus N , Muñoz Maniega Susana , Wardlaw Joanna M 
Published: March 2022

AbstractBackground and objectivesWhite matter hyperintensities (WMH) are frequent imaging features of small vessel disease (SVD) and related to poor clinical outcomes. WMH progression over time is well described, but regression was also noted recently, although the frequency and associated factors are unknown. This systematic review and meta-analysis aims to assess longitudinal intra-individual WMH volume changes in sporadic SVD.MethodsFollowing PRISMA guidelines we searched EMBASE and MEDLINE for papers up to 28 January 2022 on WMH volume changes using MRI on ≥2 time-points in adults with sporadic SVD. We classified populations (healthy/community-dwelling, stroke, cognitive, other vascular risk factors, depression) based on study characteristics. We performed random-effects meta-analyses with Knapp-Hartung adjustment to determine mean WMH volume change (change in mL, % of intracranial volume [%ICV], or mL/year), 95%CI and prediction intervals (PI, limits of increase and decrease) using unadjusted data. Risk of Bias Assessment tool for Non-randomised Studies (RoBANS) was used to assess risk of bias.ResultsForty papers, 10,932 participants, met the inclusion criteria. Mean WMH volume increased over time by: 1.74 mL (95% CI 1.23, 2.26; PI -1.24, 4.73 mL; 27 papers, N=7411, mean time interval 2.7 years, SD=1.65); 0.25%ICV (95% CI 0.14, 0.36; PI -0.06, 0.56; 6 papers, N=1071, mean time interval 3.5 years, SD =1.54); or 0.61 mL/year (95% CI 0.37, 0.85; PI -0.25, 1.46; 7 papers, N=2450). Additionally, 13 papers specifically mentioned and/or provided data on WMH regression, which occurred in asymptomatic, stroke, and cognitive presentations of SVD.DiscussionNet mean WMH volume increases over time mask wide-ranging change (e.g. mean increase of 1¾mL ranging from 1¼mL decrease to 4¾ml increase), with regression documented explicitly in up to 1/3 of participants. More knowledge on underlying mechanisms, associated factors and clinical correlates is needed, as WMH regression could be an important intervention target.
Predictors of unfavourable treatment outcome in patients diagnosed with drug-resistant tuberculosis in the Torres Strait / Papua New Guinea border region
Authors: Foster J’Belle , Mendez Diana , Marais Ben J. , Peniyamina Dunstan , McBryde Emma S. 
Published: March 2022

ABSTRACTDrug-resistant tuberculosis (DR-TB) is an ongoing challenge in the Torres Strait Islands (TSI) / Papua New Guinea (PNG) border region. Treatment success rates have historically been poor for patients diagnosed with DR-TB, leading to increased transmission. This study aimed to identify variables associated with unfavourable outcome in patients diagnosed with DR-TB to inform programmatic improvements.A retrospective study of all DR-TB cases who presented to Australian health facilities in the Torres Strait between 1 March 2000 and 31 March 2020 was performed. This time period covers four distinct TB programmatic approaches which reflect Australian and Queensland Government decisions on TB management in this remote region. Univariate and multivariate predictors of unfavourable outcome were analysed. Unfavourable outcome was defined as lost to follow up, treatment failure and death. Successful outcome was defined as cure and treatment completion.In total, 133 patients with resistance to at least one TB drug were identified. The vast majority (123/133; 92%) of DR-TB patients had pulmonary involvement; and of these, 41% (50/123) had both pulmonary and extrapulmonary TB. Unfavourable outcomes were observed in 29% (39/133) of patients. Patients living with human immunodeficiency virus, renal disease or diabetes (4/133; 4/133; 3/133) had an increased frequency of unfavourable outcome (p<0.05), but the numbers were small. Among all 133 DR-TB patients, 41% had a low lymphocyte count, which was significantly associated with unfavourable outcome (p<0.05). We noted a 50% increase in successful outcomes achieved in the 2016 - 2020 programmatic period, compared to earlier periods (OR 5.3, 95% Confidence Interval [1.3, 20.4]). Being a close contact of a known TB case was associated with improved outcome.While DR-TB treatment outcomes have improved over time, enhanced surveillance for DR-TB, better cross border collaboration and consistent diagnosis and management of comorbidities and other risk factors should further improve patient care and outcomes.
Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
Authors: McMenamin Martina E. , Nealon Joshua , Lin Yun , Wong Jessica Y. , Cheung Justin K. , Lau Eric H. Y. , Wu Peng , Leung Gabriel M. , Cowling Benjamin J. 
Published: March 2022

AbstractBackgroundHong Kong maintained extremely low circulation of SARS-CoV-2 until a major community epidemic of Omicron BA.2 starting in January 2022. Both mRNA BNT162b2 (BioNTech/Fosun Pharma) and inactivated CoronaVac (Sinovac) vaccines are widely available, however coverage has remained low in older adults. Vaccine effectiveness in this predominantly infection-naïve population is unknown.MethodsWe used individual-level case data on mild/moderate, severe/fatal and fatal hospitalized COVID-19 from December 31, 2021 to March 8, 2022, along with census information and coverage data of BNT162b2 and CoronaVac. We used a negative binomial model, adjusting for age and calendar day to estimate vaccine effectiveness of one, two and three dose schedules of both vaccines, and relative effectiveness by number of doses and vaccine type.FindingsA total of 12.7 million vaccine doses were administered in Hong Kong’s 7.3 million population, and we analyzed data from confirmed cases with mild/moderate (N=5,474), severe/fatal (N=5,294) and fatal (N=4,093) COVID-19. Two doses of either vaccine protected against severe disease and death, with higher effectiveness among adults ≥60 years with BNT162b2 (VE: 88.2%, 95% confidence interval, CI: 84.4%, 91.1%) compared to CoronaVac (VE: 74.1%, 95% CI: 67.8%, 79.2%). Three doses of either vaccine offered very high levels of protection against severe outcomes (VE: 98.1%, 95% CI: 97.1%, 98.8%).InterpretationThird doses of either BNT162b2 or CoronaVac provide substantial additional protection against severe COVID-19 and should be prioritized, particularly in older adults who received CoronaVac primary schedules. Longer follow-up is needed to assess persistence of different vaccine platforms and schedules.FundingCOVID-19 Vaccines Evaluation Program, Chinese Center for Disease Control and Prevention
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Authors: Lapointe Hope R. , Mwimanzi Francis , Cheung Peter K. , Sang Yurou , Yaseen Fatima , Umviligihozo Gisele , Kalikawe Rebecca , Speckmaier Sarah , Moran-Garcia Nadia , Datwani Sneha , Duncan Maggie C. , Agafitei Olga , Ennis Siobhan , Young Landon , Ali Hesham , Ganase Bruce , Omondi F. Harrison , Dong Winnie , Toy Junine , Sereda Paul , Burns Laura , Costiniuk Cecilia T. , Cooper Curtis , Anis Aslam H. , Leung Victor , Holmes Daniel , DeMarco Mari L. , Simons Janet , Hedgcock Malcolm , Prystajecky Natalie , Lowe Christopher F. , Pantophlet Ralph , Romney Marc G. , Barrios Rolando , Guillemi Silvia , Brumme Chanson J. , Montaner Julio S.G. , Hull Mark , Harris Marianne , Niikura Masahiro , Brockman Mark A. , Brumme Zabrina L. 
Published: March 2022

ABSTRACTBackgroundLonger-term humoral responses to two-dose COVID-19 vaccines remain incompletely characterized in people living with HIV (PLWH), as do initial responses to a third dose.MethodsWe measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement and viral neutralization against wild-type and Omicron strains up to six months following two-dose vaccination, and one month following the third dose, in 99 PLWH receiving suppressive antiretroviral therapy, and 152 controls.ResultsThough humoral responses naturally decline following two-dose vaccination, we found no evidence of lower antibody concentrations nor faster rates of antibody decline in PLWH compared to controls after accounting for sociodemographic, health and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after two doses, nor evidence that a low nadir CD4+ T-cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-dose levels, though anti-Omicron responses were consistently weaker than against wild-type.Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post-third-dose responses.ConclusionPLWH receiving suppressive antiretroviral therapy mount strong antibody responses after two- and three-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in light of Omicron.